Company Overview - Entrada Therapeutics focuses on treating devastating diseases with intracellular targets [2] - The company is advancing multiple clinical programs for Duchenne muscular dystrophy (DMD) in the U.K., EU, and U.S. [2] - By 2026, Entrada expects to have four clinical stage programs in its DMD franchise [2] Clinical Progress - Entrada highlighted significant progress across its EEV portfolio for neuromuscular and ocular diseases [2] - The company is also making progress in its partnership for myotonic dystrophy type 1 with Vertex, specifically with the program VX-670 [2] - The year is anticipated to have several value-driving catalysts for the company [2]